Loading...
Market
Change in US federal biotech research funding by FY 2025
5
Resolution / Starting Odds
Increase • 33%
Decrease • 33%
Remain the same • 34%
Federal budget reports, legislative updates
Story
U.S. Biosecurity Bill Extends Decoupling Deadline for Chinese Biotech to 2032
May 10, 2024, 02:54 PM
Recent legislative changes to the Biosecure Act are set to impact U.S. biotechnology firms by extending the timeline for decoupling from Chinese biotech companies like WuXi AppTec and WuXi Biologics. The revised bill, which now includes provisions for reimbursement and contracts by federal agencies such as CMS, the Department of Veterans Affairs, and NIH, also grandfathers existing contracts. This adjustment aims to provide a 'substantial runway' for the industry, setting a decoupling deadline of 2032. The modifications come amid concerns that a rapid disengagement could harm patients and biopharmaceutical companies, as indicated by a survey from IAmBiotech.
View original story
Similar markets
Increase in oversight or auditing • 33%
Reduction in funding • 33%
No significant changes • 34%
Increase Funding • 25%
Decrease Funding • 25%
Maintain Current Funding • 25%
Cease All Funding • 25%
Increased Funding • 33%
Maintained Current Levels • 33%
Reduced Funding • 34%
Continuation with increased oversight • 25%
Complete ban on such funding • 25%
Reduction but not complete cessation • 25%
No significant changes to funding policies • 25%
Decrease in funding • 33%
Maintain current level • 33%
Increase in funding • 34%
Increase support • 33%
Decrease support • 33%
No significant change • 34%
Increase in funding • 33%
Decrease in funding • 33%
No change in funding • 33%
Increase in funding • 33%
Decrease in funding • 33%
No change in funding • 34%
Increase • 33%
Stay the same • 34%
Decrease • 33%
Decrease in funding • 33%
No change in funding • 33%
Increase in funding • 34%
No policy changes • 33%
Policy changes enacted • 33%
Funding cut or reallocated • 33%